 FRIENDSWOOD, Texas--BUSINESS WIRE--- CSTL DecisionDxMelanoma--Castle Biosciences, Inc. Nasdaq: CSTL, a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of a cross-sectional study of dermatologists that found its respondents are increasingly incorporating DecisionDx-Melanoma into the management of their patients with melanoma. DecisionDx-Melanoma is Castles gene expression profile test that uses an individual patients t 